期刊文献+

2019新型冠状病毒感染的肺炎早期研究进展 被引量:2

Pneumonia early research progress of 2019 novel coronavirus infection
原文传递
导出
摘要 2019年12月,中国湖北武汉出现了一种新型冠状病毒引起的肺炎,并扩散传播。中国疾病预防控制中心及相关研究部门快速鉴定、公布其序列,研究并阐述了其流行病学特点。该冠状病毒被WHO命名为2019新型冠状病毒(2019 novel coronavirus,2019-nCoV),所感染的疾病命名为2019冠状病毒病“COVID-19”,国内简称“新冠肺炎”(novel coronavirus pneumonia,NCP)。中国政府及相关部门快速采取措施阻止疫情的进一步扩散,并采用老药新用策略以及中西结合的方式对病人开展救治工作。本文检索近期所发表的新冠肺炎相关论文,综述其研究进展,提出可能的新药研发思路。 In December 2019,a new coronavirus-induced pneumonia appeared in Wuhan and spread in and out of China.The sequence was quickly identified and published,and epidemiological characteristics was studied by Chinese Center for Disease Control and Prevention and some research departments.The coronavirus induced disease was named by the WHO as 2019 novel coronavirus(2019-nCoV)and novel coronavirus pneumonia(NCP)at domestic.The Chinese government and relevant departments quickly took actions to prevent the epidemic from further expanding.New strategies of using old medicines were adopted in clinical treatment,and a combination of Chinese and western methods was used to relieve the symptoms of patients.This article reviewed the new published novel coronavirus pneumonia papers and summarized the research progress,and suggested possible new drug development.
作者 张林丽 刘莉 ZHANG Lin-li;LIU Li(Center for Pharmacological Evaluation&Research,Shanghai Institute of Pharmaceutical Industry,Shanghai 200040,China;State Key Laboratory of New Drug&Pharmaceutical Process,Shanghai Institute of Pharmaceutical Industry,Shanghai 200437,China;Shanghai Professional and Technical Service Center for Biological Material Draggability Evaluation,Shanghai 200437,China)
出处 《世界临床药物》 CAS 2020年第2期143-148,共6页 World Clinical Drug
关键词 新型冠状病毒感染的肺炎 流行病 突刺蛋白 靶点 novel coronavirus pneumonia epidemic spike protein target
  • 相关文献

参考文献2

共引文献2944

同被引文献29

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部